1. Home
  2. Business
  3. DRDO to launch 1st batch of its Covid-19 drug ‘2-DG’ from next week

DRDO to launch 1st batch of its Covid-19 drug ‘2-DG’ from next week

By Saima Siddiqui 
Updated Date
DRDO to launch 1st batch of its Covid-19 drug ‘2-DG’ from next week

New Delhi: The Defence Research and Development Organisation (DRDO) has announced to launch first batch of its 2-deoxy-D-glucose (2-DG) drug for the treatment of moderate to severe Covid-19 cases, next week.

Also Read :- HDFC commits Rs 40 crore for COVID-19 relief during second wave

“The first batch of 10,000 doses of 2-DG medicine for the treatment of Covid-19 infected patients would be launched early next week and will be given to patients,” a DRDO official said.

“The drug manufacturers are working on ramping up the production of the medicine for future use. The drug has been developed by a team of DRDO scientists including Dr Anant Narayan Bhatt,” the official added.

The drug has been developed by the DRDO lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy’s Laboratories.

It will be given as an adjunct therapy or an alternative treatment, and its purpose is to assist the primary treatment. It comes in powder form in sachets, which is taken orally by dissolving it in water.

Also Read :- Russia's 'Sputnik V' vaccine to be rolled out at Rs 1,195 in Apollo hospitals

The Drugs Controller General of India (DCGI) approved 2-DG for emergency use early last week.

“Clinical trial have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence,” read a statement by DRDO upon the drug getting DCGI nod.

According to DRDO, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.

“A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC,” it said.

In April 2020, during the first wave of the Covid-19 pandemic, INMAS-DRDO scientists conducted laboratory experiments of 2-DG with the help of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad. They found that this molecule works effectively against the SARS-CoV-2 virus and inhibits viral growth.

Also Read :- FM Nirmala Sitharaman to chair 43rd GST Council meet today, expectations & agendas

Based on the results, the DCGI had in May 2020 permitted Phase-II clinical trial of 2-DG in Covid-19 patients.

In Phase-II trials (including dose-ranging) conducted from May to October 2020, the drug was found to be safe and showed significant improvement in the patients’ recovery.

Further reading:
For the latest news and reviews, follow us on Facebook and Twitter ...